Methods: Development of the DA was conducted in collaboration with clinicians, patients with OC, representatives from patient organisations and cancer societies. First, a focus group of seven former OC patients was performed followed by a quantitative rating of the DA pilot version. The DA was adapted accordingly and then tested in 14 OC patients with recurrence using a structured interview guide (alpha testing). A final adaptation was done and the DA is now ready for testing on real-time patients (beta test).
Results: The alpha test showed that patients had a good understanding of the information provided in the DA. In total, 10 of the patients indicated that the DA helped clarifying what was important, and 12 patients agreed that the DA prepared them to make a better decision and helped them reflecting on their concerns regarding CA125.
Conclusion: The DA was useful in decision making regarding monitoring CA125 during follow up after OC. The majority of participants indicated that the DA was helpful in clarifying their concerns and would be helpful in making a better decision. The effectiveness of the DA will be tested in beta test.
|Status||Udgivet - 2017|
|Begivenhed||Åben Forskerdag 2017: 'Data in research - as seen from the viewpoints of researchers and citizens - Trinity , Fredericia, Danmark|
Varighed: 26. apr. 2017 → 26. apr. 2017
|Konference||Åben Forskerdag 2017|
|Periode||26/04/2017 → 26/04/2017|